Elvira L Vos1, Masaya Nakauchi1, Marinela Capanu2, Bernard J Park3, Daniel G Coit1, Daniela Molena3, Samuel S Yoon1, David R Jones3, Vivian E Strong1. 1. From the Gastric and Mixed Tumor Service (Vos, Nakauchi, Coit, Yoon, Strong), Memorial Sloan Kettering Cancer Center, New York, NY. 2. Department of Surgery, Department of Epidemiology & Biostatistics (Capanu), Memorial Sloan Kettering Cancer Center, New York, NY. 3. Thoracic Service (Park, Molena, Jones), Memorial Sloan Kettering Cancer Center, New York, NY.
Abstract
BACKGROUND: A biologic, degradable extracellular matrix (ECM) has been shown to support esophageal tissue remodeling, which could reduce the risk of anastomotic leak following total gastrectomy and esophagectomy. We evaluated the safety and efficacy of reinforcing the anastomosis with ECM in reducing anastomotic leak as compared to a matched cohort. STUDY DESIGN: In this single-center, nonrandomized phase II trial, gastric or esophageal adenocarcinoma patients undergoing total gastrectomy or esophagectomy were recruited from November 2013 through December 2018. ECM was surgically wrapped circumferentially around the anastomosis. Anastomotic leak was assessed clinically and by contrast study and defined as clinically significant if requiring invasive treatment (grade 3 or higher). Anastomotic stenosis, other adverse events, symptoms, and dysphagia score were collected by standardized forms at regular follow-up visits at approximately postoperative days (POD) 21 and 90. Patients receiving ECM were compared to a cohort matched for surgery type and age. RESULTS: ECM placement was not feasible in 9 of 75 patients (12%), resulting in 66 patients receiving ECM. Total gastrectomy was performed in 50 patients (76%) and esophagectomy in 16 (24%). Clinically significant anastomotic leak was diagnosed in 6 of 66 patients (9.1%) (3/50 [6.0%] after gastrectomy, 3/16 [18.8%] after esophagectomy); this rate did not differ from that in the matched cohort (p = 0.57). Stenosis requiring invasive treatment occurred in 8 patients (12.5%), and 10 patients (15.6%) reported not being able to eat a normal diet at POD 90. No adverse events related to ECM were reported. CONCLUSIONS: Esophageal anastomotic reinforcement after total gastrectomy or esophagectomy with a biologic, degradable ECM was mostly feasible and safe, but was not associated with a statistically significant decrease in anastomotic leak.
BACKGROUND: A biologic, degradable extracellular matrix (ECM) has been shown to support esophageal tissue remodeling, which could reduce the risk of anastomotic leak following total gastrectomy and esophagectomy. We evaluated the safety and efficacy of reinforcing the anastomosis with ECM in reducing anastomotic leak as compared to a matched cohort. STUDY DESIGN: In this single-center, nonrandomized phase II trial, gastric or esophageal adenocarcinoma patients undergoing total gastrectomy or esophagectomy were recruited from November 2013 through December 2018. ECM was surgically wrapped circumferentially around the anastomosis. Anastomotic leak was assessed clinically and by contrast study and defined as clinically significant if requiring invasive treatment (grade 3 or higher). Anastomotic stenosis, other adverse events, symptoms, and dysphagia score were collected by standardized forms at regular follow-up visits at approximately postoperative days (POD) 21 and 90. Patients receiving ECM were compared to a cohort matched for surgery type and age. RESULTS: ECM placement was not feasible in 9 of 75 patients (12%), resulting in 66 patients receiving ECM. Total gastrectomy was performed in 50 patients (76%) and esophagectomy in 16 (24%). Clinically significant anastomotic leak was diagnosed in 6 of 66 patients (9.1%) (3/50 [6.0%] after gastrectomy, 3/16 [18.8%] after esophagectomy); this rate did not differ from that in the matched cohort (p = 0.57). Stenosis requiring invasive treatment occurred in 8 patients (12.5%), and 10 patients (15.6%) reported not being able to eat a normal diet at POD 90. No adverse events related to ECM were reported. CONCLUSIONS: Esophageal anastomotic reinforcement after total gastrectomy or esophagectomy with a biologic, degradable ECM was mostly feasible and safe, but was not associated with a statistically significant decrease in anastomotic leak.
Authors: Luke V Selby; Emily A Vertosick; Daniel D Sjoberg; Mark A Schattner; Yelena Y Janjigian; Murray F Brennan; Daniel G Coit; Vivian E Strong Journal: J Am Coll Surg Date: 2015-02-16 Impact factor: 6.113
Authors: Han Mo Yoo; Han Hong Lee; Jung Ho Shim; Hae Myung Jeon; Cho Hyun Park; Kyo Young Song Journal: J Surg Oncol Date: 2011-07-25 Impact factor: 3.454
Authors: D A Patel; R Sharda; K L Hovis; E E Nichols; N Sathe; D F Penson; I D Feurer; M L McPheeters; M F Vaezi; David O Francis Journal: Dis Esophagus Date: 2017-05-01 Impact factor: 3.429
Authors: Stephen F Badylak; Toshitaka Hoppo; Alejandro Nieponice; Thomas W Gilbert; Jon M Davison; Blair A Jobe Journal: Tissue Eng Part A Date: 2011-03-28 Impact factor: 3.845
Authors: James D Luketich; Arjun Pennathur; Yoko Franchetti; Paul J Catalano; Scott Swanson; David J Sugarbaker; Alberto De Hoyos; Michael A Maddaus; Ninh T Nguyen; Al B Benson; Hiran C Fernando Journal: Ann Surg Date: 2015-04 Impact factor: 12.969
Authors: Alejandro Nieponice; Kevin McGrath; Irfan Qureshi; Eric J Beckman; James D Luketich; Thomas W Gilbert; Stephen F Badylak Journal: Gastrointest Endosc Date: 2008-07-26 Impact factor: 9.427
Authors: Nabil P Rizk; Peter B Bach; Deborah Schrag; Manjit S Bains; Alan D Turnbull; Martin Karpeh; Murray F Brennan; Valerie W Rusch Journal: J Am Coll Surg Date: 2004-01 Impact factor: 6.113